{"name":"Entrada Therapeutics","slug":"entrada","ticker":"TRDA","exchange":"NASDAQ","domain":"entradatx.com","description":"Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.","hq":"Boston, MA","founded":0,"employees":"152","ceo":"Dipal Doshi","sector":"Rare Disease / Intracellular Biologics","stockPrice":14.22,"stockChange":0.37,"stockChangePercent":2.67,"marketCap":"$544M","metrics":{"revenue":25421000,"revenueGrowth":-96.5,"grossMargin":0,"rdSpend":142269000,"netIncome":-143750000,"cash":295697984,"dividendYield":0,"peRatio":-4.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"Entrada Therapeutics Announces FDA Clearance of IND for ENTR-701","summary":"Entrada Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for ENTR-701, a gene therapy for spinal muscular atrophy.","drugName":"ENTR-701","sentiment":"positive"},{"date":"2022-11-14","type":"deal","headline":"Entrada Therapeutics Announces Collaboration with Biogen to Develop Gene Therapies for Neurological Disorders","summary":"Entrada Therapeutics announced a collaboration with Biogen to develop gene therapies for neurological disorders, including spinal muscular atrophy.","drugName":"ENTR-701","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNaGNCZXUxWERHZXhLYVMxOFBMa2MzcE10dXRCeUpfMTZwcEJOYzZ5ZWdtVGRwcVpRU1Y1cUNnY0tFWmFVZXY2VldwQjctSWVnUjF2N08wN21YZVdCNFFNamRRVGFydEFUT0dKN3BCWlE2RnBaSHphZ0RTaFNpWHlWYmZpblM3WmxkZFVNNlF5R0dPMTk5SFkwZE94ZVNjTHp4alhXQ0dvaDZrU21NTTZYOFp3amdzMV9wYWhLamNHMHBGQ2p4bmNWdUFESWNTcVlMZURuVTNOS3FLQm4wQ2xlbEFwU3pjRWEydWpKSERjUGFYX1gwY1RONmFIaGJ0eDZ2ZVItVnRzRXhDZDdOU1JDM1JaRjNJX1ZJcms0LUtwOWo?oc=5","date":"2026-04-07","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNNHNWX0swVXBsb0Q3aVo3ZThsdTJtTWZGbm1meURPekxyTmM0Zm1HS2NkeU81VzMyTGJmNFMtUTFvZTVFbnU0bHZBU2VPWTRqdEdib21hdWVmZkoxcUpSV2ltRE1vWGdtT2J2Z3hnM3dYTFdNVkI1SFpUeXp2RENMTkJ6b09MZXpMSXFVcEZra004R0xyUUhOQWtaTEd4aXNUaGFJN1VMQmIyMERITEVjSUtJZzctRlRuTkRTVWZTY29jdEJmMEUtdA?oc=5","date":"2026-04-01","type":"pipeline","source":"MarketBeat","summary":"Entrada Therapeutics (NASDAQ:TRDA) Reaches New 1-Year High - Here's What Happened - MarketBeat","headline":"Entrada Therapeutics (NASDAQ:TRDA) Reaches New 1-Year High - Here's What Happened","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPUFBZVjZTc0VhN29yX3ZtUGRQcDN6X0FOOEF4eTl0TFFlaTlIMVhMc2NrWmFNaHktbnpyd0pPU0ppSHZyZEM0YjFfcTI3TnhOOGFuaE93dnhERGxVWnIwNEhSbG4yZHYzemxzTzJRQ0lIZ3FKV0UzaVFRR3RoVVJJaHM3MS1UQzhsRnJuRUM2UmtOZXVNRUM5OWx1N2F3OEZndVU1ZjIzelNTODEzd1EtU3gweXRuX0IwUlNxVFBpVklFYXlYUWVFclZabXE1c1lGZXVPTGZZeTVFbE9pekxHZ1VVZk1JRjBRT25MTFZQNEptdkhPRWJYdnR1djU3UkxtbmhsLXZYaEpiY1RJdFNn?oc=5","date":"2026-03-24","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE01SEIwTGJrdUdxZ21NN2pfcF9ScGNqUzl5d2ZuaUV6N01CSjVkZmQ2V043YTVVRklSeEJZOUpLY3FoR2xZUFJuMktJbFdWTFBLU1hydXhYc3poOHJ1cGtKWWlmZlZrY2RUeDRrd2V3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Entrada Therapeutics, Inc. (TRDA) - Stock Titan","headline":"If You Invested $1,000 in Entrada Therapeutics, Inc. (TRDA)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-27","type":"earnings","source":"simplywall.st","summary":"Entrada Therapeutics (TRDA) Quarterly Revenue Slump Tests Bullish Growth Narratives - simplywall.st","headline":"Entrada Therapeutics (TRDA) Quarterly Revenue Slump Tests Bullish Growth Narratives","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOOTVxV01NaG5GQTZyclUxS2xZbHZla3NITWhCS3JxdGROVjFqWHF3SzliTHp0dm5RVkNDbHZkcDFGT2N0V3NOZmVEcEFKNXdYY0UwOXRyTHgyaGRZbzR0cmV0YXptV29aOTd3dG5KQzV2dkVYSWgyLVNXdU1xWTlVS3JjSTZtalVDVWJWUF8wZUpCT0NDdmdwRWhzbjRQU1JVSXJ4VQ?oc=5","date":"2026-02-26","type":"pipeline","source":"TradingView","summary":"Entrada Therapeutics, Inc. SEC 10-K Report - TradingView","headline":"Entrada Therapeutics, Inc. SEC 10-K Report","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQbHNGdHg5QWNheHRlaXlXNWl4MzE2cndjbnBPSE50RUQ3Z1l6dW9GdnpScHdqRWt6QTZCLUlIUl92OEE5MXd3N0ZlRWdZaUpNOE9QdjVGZzJxNXhGZjc0b1V6VmdhVW8yT0U4cW9WT2o5d2t4RkRsdXdyR0JEVWJjd1dvdUdQT0hJcVhJbVBiMVBteUZhNkFVZnNPWm8yUmk2a2hFeDVLUzZyMzQ5MVBrNE9PLXM2MWZtMUZMaFY1c3lTbEstcjlVckpmcTJidWI3UU5pNTlweUw1TGZ6dFJONU5CQk8tVWhKTDZJUV9CaTdsMS03LWdSLUJiSU94T3piYk9MbmFPNi1YZDg?oc=5","date":"2026-01-09","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR)","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOczUzSFo5akhCczRqQlpXOFdLcUNHX0ZyQ09vNHpXc3AwVDFoTjJpdFFMT3ptT05NR1dhYWM3YmJIazFRakFaMkNmdS1kRlQzYUxFVDNFYlNNc0tHOWVpaEc0SEVDbEVjTkJpSlU5Nk0tZ3VQZ2otek5nZnNoNkRqd01EYnRQYklYYkQtUFR5QTd2YnlzM3U4QzJUT2t0UjhKSUo2OU1FQmlXNTd5MGVaaG5oYjZmNVI3MUtsYVZZQjR6cFB0OXc?oc=5","date":"2025-12-19","type":"pipeline","source":"Investing.com","summary":"TD Cowen analyst highlights 10+ potential biotech catalysts for 2026 - Investing.com","headline":"TD Cowen analyst highlights 10+ potential biotech catalysts for 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPZl92NmNvVHJLOTJVeGJWMlMyX2paSkw1T1hpQlotUDJqYzdfTlo1RzlSYkctd0hwZFNsamVNZk0zc3JVU0JYVEZ4WEtfWS1wSHZiTFhfVWF1cER1M3BqcU5jaE5Fc2VwbEx3dTM3VVNlb3cxV1VsNGM3dW5aX0lhU2F2U3N4MVdOWWU2dWo5U2xKNmM?oc=5","date":"2025-12-16","type":"earnings","source":"Seeking Alpha","summary":"Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY) - Seeking Alpha","headline":"Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPY3VqRFpQTWdqd0pTcnFWOGJxT2hHdi1DN2F1Vm5tVl9hVVpjWnVOMU93bXlYQ2RUSDlmTXhDc295cTZCY1lkTU5vQXRUdS1nZEcyRUJUVVYtc3UtRy1QU1hRbjFoNkdXd1RjRF81Yl9PR2lHSXVERTYzTmVhbF8xdXBDNmFGSE5FSUNHTFloYVk1TDVTdEFzRXUwaVhXR1lFVU85a3RXNF9aMTJWZDQydC03SmRVd0prb1p2WGln?oc=5","date":"2025-11-17","type":"trial","source":"Seeking Alpha","summary":"Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts - Seeking Alpha","headline":"Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-09","type":"pipeline","source":"simplywall.st","summary":"Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st","headline":"Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPX1c0Nm5wb1kzVUVpbW81N2VGbDFLMVVxV2NyUmpJSmdWdXBOR1QtWDA1UkFTU0lfdTdQeW13b1JVVWZBRWJQUmtyMFBhOTB6QlFoTGMwdG5Dd0Fha1l1ejh2UXBza3owTHdrZ0pnSWt0d2VnWGNaeUtJNFQwR0t4V2lFR183a1JXLXpjV0t3SVkzSVo2d29PNU8zVkhZV0YzZEtvR1ZGV19Rdk9kSXNZUUlhWXNFbE9wODZFcFRibXlsTFlu?oc=5","date":"2025-01-30","type":"pipeline","source":"PR Newswire","summary":"Azenta Announces the Election of Dipal Doshi to its Board of Directors - PR Newswire","headline":"Azenta Announces the Election of Dipal Doshi to its Board of Directors","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Sarepta Therapeutics","Pfizer"],"therapeuticFocus":["Rare Diseases","Intracellular Biologics"],"financials":{"source":"sec_edgar+yahoo","revenue":25421000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":25421000,"period":"2025-12-31"},{"value":210782000,"period":"2024-12-31"},{"value":210782000,"period":"2024-12-31"},{"value":129013000,"period":"2023-12-31"},{"value":129013000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":142269000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-143750000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":377378000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":152,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":14.22,"previousClose":13.85,"fiftyTwoWeekHigh":14.26,"fiftyTwoWeekLow":4.93,"fiftyTwoWeekRange":"4.93 - 14.26","fiftyDayAverage":11.82,"twoHundredDayAverage":8.55,"beta":-0.15,"enterpriseValue":253834496,"forwardPE":-4.1,"priceToBook":1.67,"priceToSales":21.42,"enterpriseToRevenue":9.98,"enterpriseToEbitda":-1.67,"pegRatio":0,"ebitda":-151902000,"ebitdaMargin":0,"freeCashflow":-76957752,"operatingCashflow":-128512000,"totalDebt":50932000,"debtToEquity":16.6,"currentRatio":12.53,"returnOnAssets":-21.6,"returnOnEquity":-39.1,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":4,"targetMeanPrice":20.5,"targetHighPrice":23,"targetLowPrice":19,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":12.7,"institutionHeldPercent":76.2,"sharesOutstanding":38284313,"floatShares":21580222,"sharesShort":924265,"shortRatio":4.09,"shortPercentOfFloat":2.4,"epsTrailing":-3.47,"epsForward":-3.44,"revenuePerShare":0.61,"bookValue":8.5,"officers":[{"age":49,"name":"Mr. Dipal  Doshi","title":"CEO & Director"},{"age":54,"name":"Mr. Nathan J. Dowden","title":"President & COO"},{"age":63,"name":"Dr. Natarajan  Sethuraman Ph.D.","title":"President of Research & Development"},{"age":46,"name":"Mr. Kory James Wentworth CPA","title":"CFO & Treasurer"},{"age":null,"name":"Dr. Jared  Cohen J.D., Ph.D.","title":"General Counsel"},{"age":null,"name":"Ms. Karla  MacDonald","title":"Chief Corporate Affairs Officer"},{"age":null,"name":"Mr. Kevin  Healy Ph.D.","title":"Senior Vice President of Regulatory Affairs"},{"age":null,"name":"Sandeep  Basnet","title":"Head of Information Technology"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.entradatx.com","phone":"857 520 9158"}}